Compare · ABBV vs ZGNX
ABBV vs ZGNX
Side-by-side comparison of AbbVie Inc. (ABBV) and Zogenix Inc. (ZGNX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and ZGNX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV carries a market cap of $505.89B.
- ABBV has hit the wire 17 times in the past 4 weeks while ZGNX has been quiet.
- ABBV has more recent analyst coverage (25 ratings vs 6 for ZGNX).
- Company
- AbbVie Inc.
- Zogenix Inc.
- Price
- -
- -
- Market cap
- $505.89B
- -
- 1M return
- +0.52%
- -
- 1Y return
- +21.22%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 2010
- News (4w)
- 17
- 0
- Recent ratings
- 25
- 6
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Zogenix Inc.
Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.
Latest ABBV
- AbbVie to Present at the Piper Sandler 38th Annual Healthcare Conference
- EVP, CHIEF OPERATIONS OFFICER Azita Saleki exercised 23,935 shares at a strike of $61.36 and covered exercise/tax liability with 13,481 shares, increasing direct ownership by 5% to 208,248 units (SEC Form 4)
- EVP, CHIEF COMMERCIAL OFFICER Stewart Jeffrey Ryan exercised 40,619 shares at a strike of $101.75, sold $11,925,738 worth of shares (40,619 units at $293.60) and gifted 3,450 shares, decreasing direct ownership by 4% to 79,721 units (SEC Form 4)
- Allergan Aesthetics Reports Improved Satisfaction With Facial Appearance Following Aesthetic Treatment in Two Studies of Patients on GLP-1 Medications
- SEC Form 10-Q filed by AbbVie Inc.
- Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026
- AbbVie Inc. filed SEC Form 8-K: Leadership Update
- Brise Pharmaceuticals Announces Global License Agreement with AbbVie to Advance the Next-Generation of Migraine Therapies
- AbbVie Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AbbVie Reports Third-Quarter 2026 Financial Results
Latest ZGNX
- ReAlta Life Sciences Announces Appointment of Jonathan Rigby to Board of Directors
- FDA Approval for FINTEPLA issued to ZOGENIX INC
- FDA Approval for FINTEPLA issued to ZOGENIX INC
- FDA Approval for FINTEPLA issued to ZOGENIX INC
- FDA Approval for FINTEPLA issued to ZOGENIX INC
- FDA Approval for FINTEPLA issued to ZOGENIX INC
- FDA Approval for FINTEPLA issued to ZOGENIX INC
- The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO
- Benzinga Pro's Top 5 Stocks To Watch For Monday, Mar. 21, 2022: BA, COIN, NILE, ZGNX, MULN
- The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings